Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 61
Filter
Add more filters










Publication year range
1.
Brain Lang ; 193: 4-9, 2019 06.
Article in English | MEDLINE | ID: mdl-29610055

ABSTRACT

PURPOSE: To examine the impact of diverse syndromes of focal and generalized epilepsy on language function in children with new and recent onset epilepsy. Of special interest was the degree of shared language abnormality across epilepsy syndromes and the unique effects associated with specific epilepsy syndromes. METHODS: Participants were 136 youth with new or recent-onset (diagnosis within past 12 months) epilepsy and 107 healthy first-degree cousin controls. The participants with epilepsy included 20 with Temporal Lobe Epilepsy (TLE; M age = 12.99  years, SD = 3.11), 41 with Benign Epilepsy with Centrotemporal Spikes (BECTS; M age = 10.32, SD = 1.67), 42 with Juvenile Myoclonic Epilepsy (JME; M age = 14.85, SD = 2.75) and 33 with absence epilepsy (M age = 10.55, SD = 2.76). All children were administered a comprehensive test battery which included multiple measures of language and language-dependent abilities (i.e., verbal intelligence, vocabulary, verbal reasoning, object naming, reception word recognition, word reading, spelling, lexical and semantic fluency, verbal list learning and delayed verbal memory). Test scores were adjusted for age and gender and analyzed via MANCOVA. RESULTS: Language abnormalities were found in all epilepsy patient groups. The most broadly affected children were those with TLE and absence epilepsy, whose performance differed significantly from controls on 8 of 11 and 9 of 11 tests respectively. Although children with JME and BECTS were less affected, significant differences from controls were found on 4 of 11 tests each. While each group had a unique profile of language deficits, commonalities were apparent across both idiopathic generalized and localization-related diagnostic categories. DISCUSSION: The localization related and generalized idiopathic childhood epilepsies examined here were associated with impact on diverse language abilities early in the course of the disorder.


Subject(s)
Cognition/physiology , Epilepsy, Generalized/diagnosis , Epilepsy, Generalized/psychology , Language Development Disorders/diagnosis , Language Development Disorders/psychology , Adolescent , Child , Epilepsy, Generalized/physiopathology , Female , Humans , Intelligence/physiology , Language , Language Development Disorders/physiopathology , Male , Neuropsychological Tests , Syndrome , Verbal Learning/physiology
2.
Neuropharmacology ; 40(1): 139-47, 2001.
Article in English | MEDLINE | ID: mdl-11077080

ABSTRACT

The anticonvulsant action and the long-term effects on learning, memory and behavior of the new generation antiepileptic drug gabapentin (GBP) were investigated in immature animals. Kainic acid (KA) was administered to rats on postnatal day (P) 35. Animals were treated with GBP or saline from P36 to P75 and spontaneous seizure frequency was monitored. After tapering the drug, the rats were tested in the water maze and open field test. Brains were then analyzed for histological lesions. Animals treated with GBP following KA-induced status epilepticus had a reduced incidence of spontaneous recurrent seizures, a better pathology score, and less aggressiveness compared to saline-treated controls. Effectiveness of GBP on seizure threshold was tested using flurothyl inhalation in 10 separate age groups of animals ranging from the newborn period to adulthood. Furthermore, GBP plasma concentration peaks were determined in all age groups. At all ages, GBP pre-treated animals demonstrated a higher seizure threshold. Plasma GBP concentrations did not significantly change with age. These data suggest that acute administration of a single therapeutic dose of GBP increases the seizure threshold at all ages studied, while chronic treatment following the status reduces spontaneous seizure frequency and cell damage and has no long-term adverse consequences on cognitive processes during development.


Subject(s)
Acetates/pharmacology , Amines , Anticonvulsants/pharmacology , Brain/drug effects , Brain/growth & development , Cyclohexanecarboxylic Acids , gamma-Aminobutyric Acid , Acetates/administration & dosage , Acetates/blood , Animals , Anticonvulsants/administration & dosage , Anticonvulsants/blood , Behavior, Animal/drug effects , Convulsants/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Flurothyl/pharmacology , Gabapentin , Injections, Intraperitoneal , Kainic Acid/pharmacology , Male , Maze Learning/drug effects , Memory/drug effects , Rats , Rats, Sprague-Dawley , Seizures/chemically induced , Seizures/pathology , Space Perception/drug effects
3.
Ment Retard Dev Disabil Res Rev ; 6(4): 281-92, 2000.
Article in English | MEDLINE | ID: mdl-11107193

ABSTRACT

Our understanding of the genetic basis of epilepsy is progressing at a rapid pace. Gene mutations causing several of the inherited epilepsies have been mapped, and several more are likely to be added in coming years. In this review, we summarize the available information on the genetic basis of human epilepsies and epilepsy syndromes, emphasizing how genetic defects may correlate with the pathophysiological mechanisms of brain hyperexcitability. Mutations leading to epilepsy have been identified in genes encoding voltage- and ligand-gated ion channels (benign familial neonatal convulsions, autosomal dominant nocturnal frontal lobe epilepsy, generalized epilepsy with febrile seizures "plus"), neurotransmitter receptors (Angelman syndrome), the molecular cascade of cellular energy production (myoclonic epilepsy with ragged red fibers), and proteins without a known role in neuronal excitability (Unverricht-Lundborg disease). Gene defects can lead to epilepsy by altering multiple and diverse aspects of neuronal function.


Subject(s)
Epilepsy/genetics , Animals , Causality , Chromosome Mapping/statistics & numerical data , Energy Metabolism/genetics , Epilepsy/pathology , Epilepsy/physiopathology , Humans , Ion Channels/genetics , Mutation/physiology , Myoclonic Epilepsies, Progressive/genetics , Myoclonic Epilepsies, Progressive/pathology , Myoclonic Epilepsies, Progressive/physiopathology , Neurons/metabolism , Neurons/pathology , Receptors, Neurotransmitter/genetics , Receptors, Neurotransmitter/metabolism
4.
J Neurosci ; 20(22): RC109, 2000 Nov 15.
Article in English | MEDLINE | ID: mdl-11069978

ABSTRACT

Choline is an essential nutrient for rats and humans, and its availability during fetal development has long-lasting cognitive effects (Blusztajn, 1998). We investigated the effects of prenatal choline supplementation on memory deficits associated with status epilepticus. Pregnant rats received a control or choline-supplemented diet during days 11-17 of gestation. Male offspring [postnatal day 29 (P29)-32] were tested for their ability to find a platform in a water maze before and after administration of a convulsant dose of pilocarpine at P34. There were no differences between groups in water maze performance before the seizure. One week after status epilepticus (P41-P44), animals that had received the control diet prenatally had a drastically impaired performance in the water maze during the 4 d testing period, whereas prenatally choline-supplemented rats showed no impairment. Neither the seizures nor the prenatal availability of choline had any effect on hippocampal choline acetyltransferase or acetylcholinesterase activities. This study demonstrates that prenatal choline supplementation can protect rats against memory deficits induced by status epilepticus.


Subject(s)
Choline/pharmacology , Dietary Supplements , Memory Disorders/drug therapy , Prenatal Exposure Delayed Effects , Status Epilepticus/complications , Acetylcholinesterase/metabolism , Animals , Behavior, Animal/drug effects , Brain/enzymology , Brain/pathology , Cell Count , Choline/metabolism , Choline O-Acetyltransferase/metabolism , Disease Models, Animal , Female , Male , Maze Learning/drug effects , Memory Disorders/etiology , Pilocarpine , Pregnancy , Rats , Rats, Sprague-Dawley , Reaction Time/drug effects , Status Epilepticus/chemically induced
5.
Semin Pediatr Neurol ; 7(3): 147-57, 2000 Sep.
Article in English | MEDLINE | ID: mdl-11023172

ABSTRACT

The developing brain is highly susceptible to seizures, as demonstrated by both human and animal studies. Until recently, the brain has been considered to be relatively resistant to damage induced by seizures early in life. Accumulating evidence in animal models now suggests that early seizures can cause structural and physiologic changes in developing neural circuits that result in permanent alterations in the balance between neuronal excitation and inhibition, deficits in cognitive function, and increased susceptibility to additional seizures. The disruption of normal neuronal activity by seizures can affect multiple developmental processes, resulting in these long-lasting changes. These data should be considered in the clinical approach to children with intractable epilepsy and suggest that early intervention may avoid some of these long-term neurologic deficits.


Subject(s)
Brain/embryology , Brain/metabolism , Child Development , Epilepsy/surgery , Seizures/metabolism , Seizures/prevention & control , Adolescent , Animals , Brain/physiopathology , Child , Epilepsy/complications , Epilepsy/etiology , Humans , Infant, Newborn , Neural Pathways/embryology , Neuronal Plasticity , Neurotransmitter Agents/metabolism , Rats , Seizures/etiology
6.
Epilepsia ; 41(8): 933-40, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10961617

ABSTRACT

PURPOSE: The ketogenic diet (KD) is a high-fat, low-carbohydrate and -protein diet that has been used to treat refractory seizures in children for more than 75 years. However, little is known about how the KD inhibits seizures or its effects on epileptogenesis. Several animal models of epilepsy have responded favorably to KD treatment, but the KD has not been studied in animals with a genetic predisposition to seizures. Here we studied the antiepileptogenic effect of the KD in EL mice, an animal model for human idiopathic epilepsy. METHODS: Young male EL mice (postnatal day 30) were randomly separated into two groups fed ad libitum with either the KD (treated, n = 21) or Agway chow (control, n = 19). The mice were weighed and tested for seizures once per week for a total of 10 weeks. The effects of the KD on plasma levels of ketone bodies and glucose were analyzed at several time points throughout the study. Associative learning was compared between treated and control animals using a water maze. RESULTS: KD treatment delayed seizure onset in young male EL mice by 1 month; however, seizure protection was transient, inasmuch as the treated and control mice experienced a similar number and intensity of seizures after 6 weeks on the diet. Plasma glucose levels and associative learning were similar in the treated and control groups, but the plasma beta-hydroxybutyrate levels were significantly higher in mice on the KD. The level of ketosis, however, was not predictive of seizure protection in EL mice. CONCLUSION: The KD delayed seizure onset in EL mice, suggesting a transient protection against epileptogenesis. The KD did not influence plasma glucose levels or associative learning. Therefore, the EL mouse may serve as a good model to study the antiepileptogenic mechanisms of the KD.


Subject(s)
Dietary Fats/metabolism , Epilepsy/diet therapy , Epilepsy/genetics , Ketosis/etiology , 3-Hydroxybutyric Acid/blood , Animals , Association Learning/physiology , Behavior, Animal/physiology , Blood Glucose/analysis , Dietary Carbohydrates/administration & dosage , Dietary Carbohydrates/metabolism , Dietary Fats/administration & dosage , Dietary Proteins/administration & dosage , Dietary Proteins/metabolism , Epilepsy/metabolism , Food, Formulated , Genetic Predisposition to Disease , Ketosis/metabolism , Male , Maze Learning/physiology , Mice , Mice, Inbred Strains , Random Allocation
8.
Brain Res Dev Brain Res ; 125(1-2): 131-8, 2000 Dec 29.
Article in English | MEDLINE | ID: mdl-11154768

ABSTRACT

Following kainic acid (KA)-induced status epilepticus (SE), the ketogenic diet (KD) retards the development of epileptogenesis, with fewer spontaneous recurrent seizures (SRS) and less mossy fiber sprouting than rats on a normal diet. In this study, we investigated whether there is a critical period for initiation of the KD, in terms of the diet's effectiveness in reducing SRS. In addition, we investigated whether early treatment with the KD prevents the deficits in spatial learning and memory that ordinarily follow KA-induced SE. Young rats (P30) underwent KA-induced SE, followed by assignment to one of three treatment groups: control diet ('KA'), KD begun 2 days after SE ('KD2'), and KD begun fourteen days after SE ('KD14'). For 12 weeks following SE, rats were monitored by closed circuit video recording (12 h/wk) to detect SRS. KD2 rats had significantly fewer SRS than rats in the control or KD14 groups. On water maze testing to assess spatial learning and memory, KD2 rats had significantly poorer acquisition of place learning than control (KA alone) or KD14 rats. KD2 rats also failed to gain weight well. There was no difference between groups on routine histologic examination of the hippocampus. In summary, P30 rats placed on the KD 2 days after SE were relatively protected from recurrent seizures, but showed behavioral and physical impairment. Rats placed on the KD 14 days after KA-induced SE did not differ from controls with regard to spontaneous seizure rate.


Subject(s)
Dietary Fats/pharmacology , Ketosis/etiology , Maze Learning/drug effects , Status Epilepticus/diet therapy , Animals , Brain/growth & development , Brain/physiopathology , Diet, Protein-Restricted , Dietary Carbohydrates/pharmacology , Excitatory Amino Acid Antagonists , Kainic Acid , Male , Rats , Rats, Sprague-Dawley , Seizures/chemically induced , Seizures/diet therapy , Seizures/physiopathology , Status Epilepticus/chemically induced , Status Epilepticus/physiopathology
9.
Brain Res Dev Brain Res ; 118(1-2): 99-107, 1999 Dec 10.
Article in English | MEDLINE | ID: mdl-10611508

ABSTRACT

Previous studies have demonstrated that recurrent seizures during the neonatal period lead to permanent changes in seizure threshold and learning and memory. The pathophysiological mechanisms for these changes are not clear. To determine if neonatal seizures cause changes in hippocampal excitability or inhibition, we subjected rats to 50 flurothyl-induced seizures during the first 10 days of life (five seizures per day). When the rats were adults, we examined seizure threshold using flurothyl inhalation, and learning and memory in the water maze. In separate groups of animals, we evaluated in vivo paired-pulse facilitation and inhibition in either CA1 with stimulation of the Schaffer collaterals or dentate gyrus with stimulation of the perforant path. Following these studies, the animals were sacrificed and the brains evaluated for mossy fiber sprouting with the Timm stain. Compared to control animals, rats with 50 flurothyl seizures had a reduced seizure threshold, impaired learning and memory in the water maze, and sprouting of mossy fibers in the CA3 pyramidal cell layer and molecular layer of the dentate gyrus. No significant differences in impaired paired-pulse inhibition was noted between the flurothyl-treated and control rats. This study demonstrates that recurrent neonatal seizures result in changes of neuronal connectivity and alterations in seizure susceptibility, learning and memory. However, the degree of impairment following 50 seizures was modest, demonstrating that the immature brain is remarkably resilient to seizure-induced damage.


Subject(s)
Animals, Newborn/physiology , Animals, Newborn/psychology , Seizures/physiopathology , Seizures/psychology , Animals , Behavior, Animal/physiology , Convulsants , Differential Threshold , Electric Stimulation , Electrophysiology , Flurothyl , Hippocampus/physiopathology , Male , Maze Learning , Neural Inhibition/physiology , Perforant Pathway/physiopathology , Rats , Rats, Sprague-Dawley , Reference Values , Seizures/chemically induced , Seizures/pathology , Swimming , Time Factors
10.
Epilepsy Res ; 37(3): 241-59, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10584974

ABSTRACT

Despite its clinical use as a therapy for refractory epilepsy for more than 75 years, the ketogenic diet (KD) remains a therapy in search of an explanation. The mechanism of action of the KD is unclear and the optimal indications for its clinical use are incompletely defined. Animal models could help to elucidate these questions. Surprisingly, there have been very few animal studies of the KD, and those that have been performed are difficult to compare because of wide discrepancies in experimental methods. Earlier models concentrated on the effect of the KD on acute seizure threshold in normal (i.e. nonepileptic) animals. Recent studies are beginning to examine the longer term effects of the KD and its role in epileptogenesis. Some features of clinical experience have been replicated in animal models, including the role of ketosis, elevation of seizure threshold by both classic ketogenic and medium chain triglyceride diets, better effectiveness at younger ages, and rapid reversal of the seizure protective effect when the diet is discontinued. These parallels raise hope that pertinent clinical questions can be addressed in the more controlled setting of the research laboratory. As in the clinical arena, there has been a recent resurgence of interest in pursuing basic questions related to the ketogenic diet, using techniques of modern neuroscience. Experimental approaches such as brain slice neurophysiology, genetic models, dissection of metabolic pathways, and neurohistological techniques hold much promise in the effort to understand this intriguing alternative to standard anticonvulsants.


Subject(s)
Brain/metabolism , Epilepsy/metabolism , Ketones/blood , Ketosis/blood , Age Factors , Animals , Dietary Fats/therapeutic use , Epilepsy/diet therapy , Fasting/metabolism , Forecasting , Seizures/chemically induced , Seizures/diet therapy , Seizures/genetics
11.
Neurology ; 53(8): 1754-61, 1999 Nov 10.
Article in English | MEDLINE | ID: mdl-10563624

ABSTRACT

BACKGROUND: Although seizures are very common in neonates and are often the harbinger of poor neurologic outcome, there is controversy regarding the degree of brain damage induced by seizures during early development. Here, we evaluated the effect of neonatal seizures on subsequent brain injury induced by status epilepticus. METHODS: Twenty-five seizures were induced by the inhalant flurothyl in neonatal rats during the first 5 days of life. Flurothyl reliably produced generalized seizures with concomitant electroencephalographic changes and a low mortality rate. During adolescence or early adulthood, animals were subjected to status epilepticus using either kainic acid or perforant path stimulation. RESULTS: Although flurothyl-induced neonatal seizures did not cause cell death, animals that had neonatal seizures had significantly more severe brain injury after both kainic acid and perforant path stimulation than did animals without a history of neonatal seizures. CONCLUSIONS: Neonatal seizures increase the susceptibility of the developing brain to subsequent seizure-induced injury.


Subject(s)
Animals, Newborn/physiology , Seizures/pathology , Status Epilepticus/pathology , Administration, Inhalation , Animals , Convulsants , Disease Susceptibility , Electric Stimulation , Electroencephalography , Excitatory Amino Acid Agonists , Flurothyl , Kainic Acid , Male , Perforant Pathway/physiopathology , Rats , Rats, Sprague-Dawley , Seizures/chemically induced , Seizures/physiopathology , Status Epilepticus/chemically induced , Status Epilepticus/etiology
12.
Dev Neurosci ; 21(3-5): 393-9, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10575263

ABSTRACT

The electrophysiological effects of the high-fat, low-carbohydrate ketogenic diet (KD) were assessed in normal and epileptic [kainic-acid(KA)-treated] adult rats using hippocampal slices. In the first set of experiments, normal rats were fed the KD or a standard control diet for 6-8 weeks (beginning on postnatal day 56, P56), after which they were sacrificed for hippocampal slices. All rats on the KD became ketotic. The baseline effects of the KD were determined by comparing extracellular measures of synaptic transmission and responses to evoked stimulation, and hippocampal excitability was tested in Mg(2+)-free medium. There were no differences in EPSP slope, input/output relationship, responses to evoked stimulation or Mg(2+)-free burst frequency between slices from control and KD-fed rats. In another set of experiments, rats were made epileptic by intraperitoneal injection of kainic acid (KA) on P54, which caused status epilepticus followed by the development of spontaneous recurrent seizures (SRS) over the next few weeks. Two days after KA-induced status, rats were divided into a control-fed group and a KD-fed group. Animals on the KD had significantly fewer SRS over the ensuing 8 weeks. In hippocampal slices from KA-treated, KD-fed rats, there were fewer evoked CA1 population spikes than from slices of control-fed rats. These results suggest that the KD does not alter baseline electrophysiological parameters in normal rats. In rats made chronically epileptic by administration of KA, KD treatment was associated with fewer spontaneous seizures and reduced CA1 excitability in vitro. Therefore, at least part of the KD mechanism of action may involve long-term changes in network excitability.


Subject(s)
Diet , Dietary Carbohydrates/administration & dosage , Dietary Fats/administration & dosage , Hippocampus/physiopathology , Ketosis/etiology , Ketosis/physiopathology , Animals , Electrophysiology , In Vitro Techniques , Kainic Acid , Male , Rats , Rats, Sprague-Dawley , Reference Values , Status Epilepticus/chemically induced , Status Epilepticus/physiopathology , Synaptic Transmission/physiology
13.
Epilepsia ; 40(10): 1329-52, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10528928

ABSTRACT

Progress in understanding the genetics of epilepsy is proceeding at a dizzying pace. Due in large part to rapid progress in molecular genetics, gene defects underlying many of the inherited epilepsies have been mapped, and several more are likely to be added each year. In this review, we summarize the available information on the genetic basis of human epilepsies and epilepsy syndromes, and correlate these advances with rapidly expanding information about the mechanisms of epilepsy gained from both spontaneous and transgenic animal models. We also provide practical suggestions for clinicians confronted with families in which multiple members are afflicted with epilepsy.


Subject(s)
Epilepsy/genetics , Animals , Animals, Genetically Modified , Chromosome Aberrations/genetics , Chromosome Disorders , Chromosome Mapping , Disease Models, Animal , Humans , Mice , Models, Genetic , Molecular Biology/trends
14.
Neuroscience ; 92(4): 1443-54, 1999.
Article in English | MEDLINE | ID: mdl-10426498

ABSTRACT

It is well documented that prolonged seizures (status epilepticus) can cause neuronal injury and result in synaptic reorganization in certain brain regions. However, the effect of recurrent, relatively short seizures in young animals on subsequent brain development is not known. To study the consequences of recurrent seizures on the developing brain, we subjected immature rats to a total of 50 flurothyl-induced seizures from postnatal day 11 until day 23. Immunohistochemistry for c-fos was performed to characterize the pattern of neuronal activation following the seizures. Cell counting of dentate granule cells, CA3, CA1, and hilar neurons, using unbiased stereological methods, and the silver impregnation method were used to evaluate neuronal death following the recurrent seizures. Timm and Golgi staining were performed four weeks after the 50th seizure to evaluate the effects of recurrent seizures on synaptic organization. Our results show that recurrent flurothyl-induced seizures progressively increased excitability of the brain, as revealed by a dramatic increase in the extent and intensity of c-fos immunostaining. While no cell loss was detected in the hippocampus with either Cresyl Violet or silver stains, animals experiencing multiple daily seizures developed increased mossy fiber sprouting in both the supragranular layer of the dentate gyrus and the infrapyramidale layer of the CA3 region. Golgi staining confirmed that there was an increase in mossy fibers in the pyramidal cell layer. Our results suggest that serial recurrent seizures in the immature brain can lead to significant changes in mossy fiber distribution even though the seizures do not cause significant hippocampal cell loss.


Subject(s)
Brain/growth & development , Brain/pathology , Seizures/pathology , Animals , Animals, Newborn , Cell Count , Coloring Agents , Convulsants , Dentate Gyrus/pathology , Gene Expression Regulation/physiology , Genes, Immediate-Early/genetics , Hippocampus/pathology , Immunohistochemistry , Male , Mossy Fibers, Hippocampal/pathology , Nerve Degeneration/pathology , Proto-Oncogene Proteins c-fos/biosynthesis , Rats , Rats, Wistar , Recurrence , Seizures/chemically induced
15.
Brain Dev ; 21(5): 318-25, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10413019

ABSTRACT

Whether febrile seizures lead to hippocampal necrosis is a question of paramount clinical importance. This study attempted to simulate a complex febrile seizure, compared with hyperthermia (HYP) alone and prolonged seizure alone (produced by continuous hippocampal stimulation (CHS)). Four groups of rats were studied at each of two ages, immature (postnatal day, P20) and adult (P60). Group 1 was subjected to 45 min of HYP (body temperature 40 degrees C) plus CHS, Group 2 received 45 min of HYP alone, Group 3 got 45 min of CHS alone, and Group 4 was sham-handled control rats. Baseline and post-session EEGs were recorded in all groups. Subsequently, brains were examined histologically for evidence of hippocampal damage. Both CHS-treated groups (with and without HYP) exhibited behavioral and EEG seizures while the group undergoing HYP alone did not have seizures. There were no gross histological lesions in any group. Cell counts in regions CA1, CA3, dentate gyrus and dentate hilus did not differ in rats under any condition of hyperthermia and CHS, in either P20 or P60 rats compared to age-matched controls. These results indicate that both immature and mature rodents are resistant to hyperthermic brain damage and raises the question of whether febrile seizures play a role in the genesis of mesial temporal sclerosis.


Subject(s)
Aging/physiology , Brain/physiology , Fever/physiopathology , Hippocampus/physiology , Animals , Behavior, Animal/physiology , Brain/cytology , Brain/growth & development , Cell Count , Electroencephalography , Fever/pathology , Hippocampus/cytology , Hippocampus/pathology , Male , Rats , Rats, Sprague-Dawley
16.
Neuroreport ; 10(7): 1517-22, 1999 May 14.
Article in English | MEDLINE | ID: mdl-10380973

ABSTRACT

The high fat, low carbohydrate, low protein ketogenic diet (KD) has been used to control refractory epilepsy in children since 1920, although its mechanism of action is unknown. Previous animal studies have shown that the KD can increase acute seizure threshold, but the effect of the KD on the process of epileptogenesis has not been studied. We tested the effect of an experimental KD on epileptogenesis in adult rats using the kainic acid (KA) model. P54 rats underwent KA-induced status epilepticus, followed by assignment to a control diet or a KD consisting of (by weight), 14% protein, 70% fat and no carbohydrate. KD-fed animals tolerated the diet and maintained ketosis. KD-fed rats had significantly fewer and briefer spontaneous recurrent seizures and less supragranular mossy fiber sprouting, although the degree of hippocampal pyramidal cell damage was similar in both groups. These results provide the first evidence that the KD retards epileptogenesis in an experimental model.


Subject(s)
Dietary Fats/pharmacology , Kainic Acid/toxicity , Ketosis , Mossy Fibers, Hippocampal/drug effects , Nerve Regeneration , Seizures/diet therapy , Animals , Disease Models, Animal , Male , Rats , Rats, Sprague-Dawley , Recurrence , Seizures/chemically induced
17.
Neuroscience ; 91(1): 293-303, 1999.
Article in English | MEDLINE | ID: mdl-10336079

ABSTRACT

Although the immature brain is highly susceptible to seizures, it is more resistant to seizure-induced neuronal loss than the adult brain. The developing brain contains high levels of neurotrophins which are involved in growth, differentiation and survival of neurons. To test the hypothesis that neurotrophins may protect the developing brain from seizure-induced neuronal loss, brain-derived neurotrophic factor up-regulation was blocked by intracerebroventricular infusion of an 18mer antisense oligodeoxynucleotide sequence to brain-derived neurotrophic factor in 19-day-old rats using micro-osmotic pumps. Control rats were infused with sense or missense oligodeoxynucleotide. Status epilepticus was induced by intraperitoneal administration of kainic acid 24 h after the start of oligodeoxynucleotide infusion. Seizure duration was significantly increased in the antisense oligodeoxynucleotide plus kainic acid group compared to groups that received kainic acid alone or kainic acid plus sense or missense oligodeoxynucleotide. There was no difference between groups in the latency to forelimb clonus. A twofold increase in brain-derived neurotrophic factor levels was observed in the hippocampus 20 h following kainic acid-induced seizures. This kainic acid-induced increase was absent in animals receiving infusion of antisense oligodeoxynucleotide to brain-derived neurotrophic factor at time of seizure induction. Hippocampi of rats in this group (antisense oligodeoxynucleotide plus kainic acid) showed a loss of CA1 and CA3 pyramidal cells and hilar interneurons. This neuronal loss was not dependent upon seizure duration since animals injected with diazepam to control seizure activity in the antisense plus kainic acid group also showed similar neuronal loss. Administration of kainic acid or infusion of antisense alone did not produce any cell loss in these regions. Induction of seizures at postnatal day 20, in the presence or absence of antisense oligonucleotide, did not produce an impairment in learning and memory when tested 15 days later in the Morris water maze. The hippocampi of these animals did not show any synaptic reorganization as assessed by growth-associated protein-43 immunostaining and Timm staining. Our findings confirm prior studies demonstrating that seizures in the immature brain are associated with little, if any, cell loss. However, when seizure-induced increase in brain-derived neurotrophic factor is blocked, seizures do result in neuronal loss in the developing brain. Thus, brain-derived neurotrophic factor appears to provide protection against kainic acid seizure-induced neuronal damage in the developing brain.


Subject(s)
Brain-Derived Neurotrophic Factor/pharmacology , Brain/pathology , Neuroprotective Agents/pharmacology , Seizures/pathology , Animals , Brain Chemistry/drug effects , Brain-Derived Neurotrophic Factor/analysis , Cell Count , Enzyme-Linked Immunosorbent Assay , GAP-43 Protein/metabolism , Immunohistochemistry , Male , Maze Learning/drug effects , Neurons/pathology , Oligonucleotides, Antisense/pharmacology , Rats , Rats, Sprague-Dawley , Seizures/psychology , Synapses/drug effects
18.
Brain Res Dev Brain Res ; 113(1-2): 139-42, 1999 Mar 12.
Article in English | MEDLINE | ID: mdl-10064883

ABSTRACT

To investigate if AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor activation contributes to acute manifestations and long term consequences of status epilepticus (SE), we administered the AMPA receptor antagonist NBQX to P35 rats undergoing kainic acid (KA)-induced SE. NBQX (30 mg/kg/dose) given intraperitoneally (i.p.) at 30, 60 and 90 min after i.p. KA injection (12 mg/kg) reduced severity of SE. When tested as adults, rats that had received KA and NBQX were similar to controls with no long term impairment in visuospatial memory (assessed by the water maze test), or histologic damage in the CA1 or CA3 hippocampal subfields. However, both P35 groups, those receiving KA alone and those receiving KA and NBQX, had similar rates of spontaneous recurrent seizures (SRS). In P15 rats, NBQX resulted in increased acute mortality from KA associated SE. These results indicate that the effects of NBQX on KA-induced SE are age dependent, and that non-NMDA receptor activation contributes to the acute manifestations and to the long term sequelae seen after KA-induced SE in the prepubescent rat brain.


Subject(s)
Brain/growth & development , Brain/physiopathology , Receptors, AMPA/antagonists & inhibitors , Receptors, AMPA/physiology , Status Epilepticus/physiopathology , Animals , Brain Chemistry/physiology , Excitatory Amino Acid Agonists/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Kainic Acid/pharmacology , Maze Learning/drug effects , Maze Learning/physiology , Quinoxalines/pharmacology , Rats , Receptors, AMPA/agonists
19.
Epilepsia ; 39(11): 1216-25, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9821988

ABSTRACT

In November 1996, a panel of pediatric neurologists met to update the consensus statement issued in 1989 by a panel of neurologists and metabolic experts on L-carnitine supplementation in childhood epilepsy. The panelists agreed that intravenous L-carnitine supplementation is clearly indicated for valproate (VPA)-induced hepatotoxicity, overdose, and other acute metabolic crises associated with carnitine deficiency. Oral supplementation is clearly indicated for the primary plasmalemmal carnitine transporter defect. The panelists concurred that oral L-carnitine supplementation is strongly suggested for the following groups as well: patients with certain secondary carnitine-deficiency syndromes, symptomatic VPA-associated hyperammonemia, multiple risk factors for VPA hepatotoxicity, or renal-associated syndromes; infants and young children taking VPA; patients with epilepsy using the ketogenic diet who have hypocarnitinemia; patients receiving dialysis; and premature infants who are receiving total parenteral nutrition. The panel recommended an oral L-carnitine dosage of 100 mg/kg/day, up to a maximum of 2 g/day. Intravenous supplementation for medical emergency situations usually exceeds this recommended dosage.


Subject(s)
Carnitine/deficiency , Carnitine/therapeutic use , Epilepsy/drug therapy , Age Factors , Ammonia/blood , Anticonvulsants/adverse effects , Anticonvulsants/pharmacokinetics , Anticonvulsants/therapeutic use , Carnitine/administration & dosage , Chemical and Drug Induced Liver Injury , Child , Child, Preschool , Epilepsy/blood , Epilepsy/diet therapy , Food, Formulated , Humans , Infant , Valproic Acid/adverse effects , Valproic Acid/pharmacokinetics , Valproic Acid/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...